Abstract
Selenium and soybean peptides have been proved to have hepatoprotective effect separately. However, the hepatoprotective effect of selenium-biofortified soybean peptides (SSPs) was few studied and its mechanism was not explored. In this study, the mechanisms of SSPs in anti-fibrosis effect in vivo and in vitro were studied. Liver fibrosis in mice was induced by CCl4 twice a week for 4 weeks and was verified by Masson staining. SSPs administration effectively decreased the extracellular matrix (ECM) and transforming growth factor (TGF-β) content (p < 0.05) compared to the model group. The significant increase of Smad7 gene expression and decrease of apoptosis rate caused by CCl4 in L-O2 cells were observed after SSPs treatment. Moreover, matrix metalloproteinase (MMPs) and apoptosis genes expressions increased significantly (p < 0.05) after treated with SSPs in HSC-T6 cells. Overall, SSPs could attenuate liver fibrosis through several pathways and could be considered as a potential therapeutic drug for treating liver fibrosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
